Illumina, Inc. ILMN
Healthcare · Diagnostics & Research · United States · S&P 500
Based on the available data, Illumina, Inc. gets an algorithmic score of 58/100. It trades at 272.00 $, with a bullish technical trend (RSI 74.3) and 49.2% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- High ROE (32.3%): generates strong profit on equity.
Weaknesses
- Shrinking revenue (-1.8% per year).
- Demanding valuation (P/E 44.6): the market prices in a lot of growth.
Fundamentals
| P/E | 50.65 |
| Forward P/E | 44.55 |
| PEG | 3.05 |
| P/B | 14.47 |
| EV/EBITDA | 36.74 |
| P/S | 9.14 |
| ROE % | 32.34 |
| ROA % | 8.67 |
| Gross margin % | 67.93 |
| Operating margin % | 21.14 |
| Net margin % | 18.34 |
| Revenue growth % (y/y) | 9.40 |
| Earnings growth % (y/y) | -9.40 |
| Revenue CAGR % | -1.78 |
| Debt/Equity % | 89.04 |
| Current ratio | 1.80 |
| FCF yield % | 2.27 |
| Dividend yield % | 0.00 |
| Payout % | 0.00 |
Returns
| 1 month | +26.2 % |
| 3 months | +54.7 % |
| 6 months | +125.2 % |
| YTD | +102.5 % |
| 1 year | +196.7 % |
| 3 years | +111.1 % |
| 5 years | -35.7 % |
Risk
| 1-year volatility | 49.2 % |
| Beta | 1.08 |
| 5-year max drawdown | -83.4 % |
| Sharpe 1A | 2.37 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.